Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

AstraZeneca and Merck are the main drugmakers testing oral versions of so-called PCSK9 Inhibitors, which reduce levels of low-density lipoprotein (LDL) cholesterol, or what is known as "bad ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is testing a once-daily PCSK9 ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.